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Abstract
Background: Age increases the risk of mortality and poor prognosis following stroke. The benefit of intravenous
thrombolysis in very old patients remains uncertain. The purpose of the study was to evaluate the efficacy and
safety of thrombolysis in very old patients considering their perfusion-imaging profile.
Methods: We conducted a retrospective study including patients older than 90 y.o. admitted for an acute ischemic
stroke. A computed tomography perfusion-imaging (CTP) was performed in patients who received thrombolysis.
Primary outcome was the functional status at 3 months, assessed by the modified Rankin scale (mRS). Secondary
outcomes were the rate of hemorrhagic transformations, duration of hospitalization and the rate of death in the
first 7 days. Patients receiving thrombolysis were compared with an age-matched group of non-thrombolysed
patients.
Results: 78 patients were included (31 % male, aged 92 ± 1.7 y.o). 37 patients received thrombolysis and among them,
30 had CTP with a mismatch. The three months mRS was not significantly different in the two groups (mRS 0–2: 5 %
and 7 % in the thrombolysed and non-thrombolysed group, respectively). Hemorrhagic transformations were more
frequent in the thrombolysed group (54 % versus 12 %, p = 0.002) and symptomatic intracranial hemorrhage tended to
be associated with mRS at three months and death in the first 7 days. Duration of hospitalization was longer in the
thrombolysed group (10 days ± 12 versus 7 days ± 9, p = 0.046).
Conclusions: Patients who received thrombolysis did not have a better functional prognosis than non-thrombolysed
patients.
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Background
Stroke care in older people is becoming a public health
problem given the increased ageing of the population
[1]. Indeed, the incidence of stroke increases with age
and about 30 % of stroke patients are older than 80 years
old [2]. It is widely admitted that oldest patients have a
worse post-stroke functional outcome and a higher rate
of death [3, 4]. Mortality at three months increases by
72 % whereas probability of good outcome decreases by
25 % every ten years [5].
The benefit of intravenous thrombolysis (IV-tPA) in is-
chemic stroke (IS) patients has been widely demon-
strated [6, 7] but most of the studies excluded patients
older than 80, therefore potentially limiting thrombolysis
in this population. Several observational studies found
that, compared to younger patients, tPA infusion to pa-
tients older than 80 y.o. was associated with higher func-
tional dependency [3, 4, 8, 9]. While no significant
increase of hemorrhagic transformation was observed in
these older patients, this worse functional outcome
seemed to be related to a worse pre-stroke functional
status, a higher clinical severity at baseline, and more
frequent post-stroke complications during the acute
(pneumonia, heart failure). Despite the less favorable
outcome of older patients, recent studies have suggested
that IV-tPA could improve the functional prognosis of
patients aged between 80 and 90 y.o. [10, 11]. However,
old age remains a limitation for using IV-tPA for many
physicians [12, 13]. That is even more true in the sub-
group of very old patients, those aged over 90 y.o., for
whom available data are scarce. In this population, few
studies [4, 10] failed to identify a benefit of IV-tPA on
functional outcome or mortality at three months. None
of these studies have evaluated the potential benefit of
IV-tPA depending on the neuroradiological imaging pat-
tern at baseline. While still a matter of debate, some
studies have suggested that a perfusion mismatch was
associated with a better post-stroke functional prognosis
among patients receiving IV-tPA [14]. The aim of our
study was to evaluate the influence of IV-tPA on the
three months functional outcome in a population of pa-
tients aged over 90 y.o., considering their perfusion-
imaging profile.
Methods
Study design and patients
Patients older than 90 y.o. admitted in the emergency
department of the Bordeaux University hospital for an
acute IS between October 2012 and June 2015 were
retrospectively included. IS was diagnosed by a stroke
neurologist based on clinical and imaging data. Inclusion
criteria were an admission in the first twelve hours fol-
lowing symptoms onset, a pre-stroke modified Rankin
scale (mRS) < 4, an absence of pre-stroke severe cognitive
impairment, an available computerized neurovascular
medical record and a set of brain images including a com-
puted tomography (CT) and angio-CT of the cervical and
intracranial arteries at baseline and a follow-up brain
imaging (brain magnetic resonance imaging [MRI] or CT-
scan in case of MRI contraindication) within 72 h, con-
firming the IS. Moreover, for patients receiving IV-tPA, a
CT-perfusion (CTP) imaging at baseline had to be avail-
able. IV-tPA was administered according to the ESO
guidelines [15] at the dose of 0.9 mg/kg until 4.5 h after
symptoms onset in absence of usual contraindications.
Patients admitted after the first 4.5 h were not thrombo-
lysed and CTP were not performed. They formed a non-
thrombolysed age-matched group for comparisons with
the thrombolysed group. Patients with transient ischemic
attack were excluded from the study.
Demographic and clinical data
Demographic and clinical data were recorded for each
patient from their computerized medical record. Pre-
stroke functional and cognitive status were evaluated
using the pre-stroke mRS [16] and the Informant
Questionnaire on Cognitive Decline in the Elderly
(IQCODE) [17]. Stroke severity at baseline and at 24 h
was evaluated by a stroke neurologist using the NIHSS
[18]. The delay between symptom onset and IV-tPA
administration, the duration of hospitalization and post-
stroke in-hospital complications (delirium, mood disor-
ders, swallowing disorders, seizure, acute coronary
syndrome, pulmonary and urinary tract infection) were
recorded. Stroke subtypes were defined according to the
TOAST classification (Trial of Org 10172 in Acute
Stroke Treatment) [19].
A clinical assessment was realized at three months
post-stroke by a neurologist or a geriatrist and functional
outcome was evaluated using the mRS. A three months
mRS ranged 0 to 2 (i.e. alive and independent) indicated
favorable outcome. The destination at the end of
hospitalization (home, rehabilitation center, other med-
ical department or nursing home) was also recorded.
Imaging acquisition and analysis
Images were acquired at the Bordeaux University hos-
pital on a 64-slice CT (General Electric Optima 660).
Analysis was performed by two neurologists who had ex-
perience in CT and MRI examination (GP and SS). CTP
source images were loaded on an Advantage workstation
Volume Share 5 (General Electric Healthcare). Perfusion
maps were automatically generated including mean tran-
sit time (MTT), cerebral blood volume (CBV) and cere-
bral blood flow (CBF) maps, using CT Perfusion 4
(General Electric Healthcare), a commercially available
software based on a delay-insensitive algorithm that is
unaffected by delay between arterial input and tissue
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curves. A mismatch was visually defined by a MTT –
CBV difference greater than 20 % [20]. The Alberta
Stroke Program Early CT score (ASPECTS) [21] was cal-
culated on the non-contrast CT. ASPECTS is a score
ranged from 0 to 10 and reflects the infarct burden (a
low score meaning a more severe infarct). The presence
and location of intracranial arterial occlusion were iden-
tified on CT-angiography of cervical and intracranial
arteries. Hemorrhagic transformation was assessed on
follow-up brain imaging according to the radiological
criteria of ECASS I [7]: hemorrhagic infarction (HI 1
and 2) or parenchymal hemorrhage (PH 1 and 2). Symp-
tomatic intracranial hemorrhage was defined by the
presence of a hemorrhagic transformation accompanied
by neurological deterioration reflected by a worsening of
the NIHSS at 24 h of at least two points. Microbleeds
were assessed on T2* MRI sequences according to the
STRIVE criteria [22] and were classified depending on
their number: absence, between 1 and 5, and > 5.
Outcomes
Primary outcome was the mRS at three months. Second-
ary outcomes were the presence of a hemorrhagic trans-
formation on the follow-up brain imaging, duration of
hospitalization and death in the first 7 days.
Statistical analysis
Qualitative variables were expressed as numbers and
percentages, and quantitative variables as means and
standard deviations (SD). Comparisons of quantitative
variables were assessed using a t-test or a Wilcoxon test
after verifying the conditions of application, and com-
parisons of qualitative variables were assessed using a
Chi2 test. Variables associated with thrombolysis were
included in a bivariate analysis with primary and second-
ary outcomes as dependent variables, using a linear re-
gression model. A multivariate analysis was performed
for each outcome using multiple linear regressions, and
including all variables with p < 0.1 in the bivariate ana-
lysis. A p-value < 0.05 was considered significant. Statis-




Seventy -eight patients were included (Fig. 1), 35 % male,
aged 91.9 ± 1.7 (mean ± SD) y.o. Demographic data are
described in Table 1. 37 patients received IV-tPA.
Among them, 30 patients had perfusion maps of suffi-
cient quality to be analyzed and all of them had a mis-
match. 41 patients did not receive IV-tPA. All of the
patients were hospitalized in an intensive care unit, and
those who did not receive IV-tPA had a 250 mg bolus of
Aspirin in the first twelve hours. Patients who were taking
anticoagulants before stroke also received aspirin as blood
biological tests showed no efficacy of their treatment. The
two groups were similar in terms of age, pre-stroke func-
tional and cognitive status. Patients who received IV-tPA
109 patients with suspicion 
of acute ischemic stroke 
screened
31 patients: diagnosis of 
acute ischemic stroke not 
confirmed on brain imaging 
78 patients with confirmed 
acute ischemic stroke on 
brain imaging included in 
the analysis
37 thrombolysed patients 
with onset to treatment time 
< 4.5 hours
30 patients with CT 
perfusion maps of 
sufficient quality
41 non-thrombolysed 
patients with onset to 
treatment time between 4.5 
and 12 hours 
Fig. 1 Patient’s flow chart
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had significantly more history of hypercholesterolemia
(41 % versus 20 %, p = 0.04) and more statins as current
treatment (32 % versus 10 %, p = 0.01). Their mean total
cholesterol level at baseline did not differ (1.9 g/L ± SD 0.3
versus 1.9 g/L ± SD 0.4, p = 0.7, in the thrombolysed and
non-thrombolysed group, respectively).
Clinical and radiological data at baseline are presented
in Table 2. Stroke severity was not significantly different
between the two groups (mean NIHSS 16 ± SD 7 in
the thrombolysed group versus 13 ± 6 in the non-
thrombolysed group, p = 0.06). The ASPECTS measured
on non-contrast CT was similar in the two groups. Intra-
cranial occlusion was significantly more frequent in the
thrombolysed group (73 % versus 34 %, p = 0.002) with a
predominance of M1 and M2 occlusion of the middle
cerebral artery.
Post-stroke outcomes and complications
Primary and secondary outcomes are described in Table 2.
The functional prognosis at three months was poor but
similar in the two groups (7 % and 14 % mRS ≤ 2 at three
months in the thrombolysed and non-thrombolysed
group, respectively). Duration of hospitalization tended to
be longer in the thrombolysed group (10 days ± 12 versus
7 days ± 9, p = 0.046). The mortality rate in the first seven
days was higher in patients receiving IV-tPA but not sig-
nificantly different from the other group (22 % versus
10 %). The most frequent post-stroke complications were
swallowing disorders (38 %), pulmonary infections (32 %)
and delirium (30 %). The rates of swallowing disorders
and delirium were significantly higher in patients receiving
IV-tPA (p = 0.003 and 0.01, respectively). The rate of
hemorrhagic transformations was also higher in the
thrombolysed group (54 % versus 17 %, p = 0.002), with a
predominance of parenchymal hemorrhages and a trend
to more symptomatic intracranial hemorrhage (40 % in
the thromboysed group and no symptomatic intracranial
hemorrhage in the non-thrombolysed group, p = 0.08).
In bivariate analyses (Table 3), hemorrhagic transform-
ation was associated with NIHSS at baseline and at 24 h
(β = 0.02, p = 0.01 and β = 0.03, p = 0.003, respectively),
presence of an intracranial occlusion (β = 0.4, p = 0.002)
and thrombolysis (β = 0.4, p = 0.002). mRS at three
months was also associated with NIHSS at baseline
(β = 0.08, p = 0.008) and at 24 h (β = 0.09, p < .001), pres-
ence of an intracranial occlusion (β = 1.04, p = 0.01), to-
gether with hemorrhagic transformation (β = 0.8, p = 0.04)
and symptomatic intracranial hemorrhage (β = 1, p = 0.03).
Death in the first seven days was also associated with
symptomatic intracranial hemorrhage (β = 0.6, p < .001) to-
gether with NIHSS at baseline and at 24 h. There was no
significant association with duration of hospitalization.
Additional bivariate analyses were performed with swal-
lowing disorders and delirium as dependent variables.
Swallowing disorders were associated with NIHSS at 24 h
(β = 0.02, p = 0.02), and thrombolysis (β = 0.3, p = 0.003).
Delirium was also associated with thrombolysis (β = 0.2,
p = 0.01) and the presence of an intracranial occlusion
(β = 0.2, p = 0.047).
In multivariate analyses (Table 4), only the NIHSS at
24 h (β = 0.03, p = 0.006) and the presence of an intra-
cranial occlusion (β = 0.3, p = 0.02) remained associated
with hemorrhagic transformation. No significant associ-
ation persisted with mRS at three month, death in the
first seven days (see Additional file 1), swallowing disor-
ders and delirium.
Discussion
The main result of this study is the absence of significant
difference on functional outcome at three months be-
tween patients older than 90 y.o. receiving and not re-
ceiving IV-tPA for an acute IS. In line with previous
studies, this result suggests poor outcome in this very
elderly population treated with IV-tPA for acute IS [4, 10].
Table 1 Demographic data
Thrombolysed Non-thrombolysed p
N = 37 N = 41
Male, n (%) 17 (46) 10 (24) 0.05
Age, mean (SD) 91.7 (1.5) 92 (1.8) NS
Vascular risk factors, n (%)
Hypertension 33 (89) 35 (85) NS
Hypercholesterolemia 15 (41) 8 (20) 0.04
Diabetes mellitus 5 (14) 4 (10) NS
Current smoking 1 (3) 0 NS
Medical history, n (%)
Atrial fibrillation 12 (32) 9 (22) NS
Ischemic heart disease 3 (8) 3 (7) NS
Heart failure 3 (8) 5 (12) NS
Stroke or transient ischemic
attack
6 (16) 10 (24) NS
Current treatment, n (%)
Antiplatelets 19 (51) 20 (49) NS
Oral anticoagulants 2 (5) 6 (15) NS
Antihypertensive drugs 28 (76) 28 (68) NS
Statins 12 (32) 4 (10) 0.01
Antidepressant drugs 6 (16) 3 (7) NS
Pre-stroke status
IQCODE, mean (SD) 3.2 (0.7) 3.3 (0.5) NS
mRS > 1, n (%) 14 (38) 19 (46) NS
At home, n (%) 32 (87) 29 (71) NS
Nursing home, n (%) 5 (14) 12 (29) NS
SD Standard deviation, IQCODE Informant Questionnaire on Cognitive Decline
in the Elderly, mRS modified Rankin Scale, NS Non-significant
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However, a recent sub-group analysis of the Third Inter-
national Stroke Trial (IST-3) reported a good outcome in
111 patients > 90 y.o. treated with alteplase versus 98 con-
trol patients, and this good outcome was not significantly
different from the other groups [23]. Our different results
might be explained by the lack of power of our study.
Interestingly, our results were observed despite a fa-
vorable neuroimaging pattern on CTP imaging with the
presence of a MTT-CBV mismatch in all available perfu-
sion maps of the patients receiving IV-tPA and presence
of a high ASPECT score [24, 25]. The impact of CTP
imaging profile in patients receiving IV-tPA is not clearly
established in the literature. This result suggests that
even with the presence of a favorable perfusion profile,
the response to thrombolysis in terms of efficacy and
safety in the sub-population of very old patients was not
improved. A worse collateral supply in older compared
to younger patients could partly explain this result. In-
deed, the long term exposure to vascular risk factors could
have reduced the permeability of collateral vessels [26].
Patients included in the present study had relatively
high NIHSS at baseline, which, in combination with the
old age could have increased the risk of poor prognosis.
This result is in accordance with previous reports which
suggested that a positive SPAN-100 (patient age + NIHSS
at baseline ≥ 100) could predict no significant benefit of
thrombolysis [27]. Unfortunately, the use of CTP parame-
ters did not seem to modify this cut-off.
Table 2 Acute clinical and radiological status, post-stroke




N = 37 N = 41
Acute clinical status, mean
(SD)
NIHSS at baseline 16 (7) 13 (6) 0.06
NIHSS at 24 h 15 (8) 12 (7) NS
Systolic blood pressure
(mmHg)
151 (28) 164 (25) 0.03
Diastolic blood pressure
(mmHg)
79 (18) 85 (22) NS
Temperature (Celsius
degree)
36.4 (0.6) 36.6 (0.6) NS
Capillary blood glucose level
(g/L)
1.2 (0.3) 1.2 (0.4) NS
Onset to needle time, mean
(SD)
168 min (48) - -
Imaging parameters
Mismatch, n (%) 30 (81) - -
Non-contrast CT ASPECTS,
mean (SD)
8.3 (2.2) 8.4 (3.3) NS
Intracranial occlusion, n
(%)
27 (73) 14 (34) 0.002
M1 12 (45) 7 (50) NS
M2 10 (37) 3 (22) 0.02
M3 2 (7) 1 (7) NS
ACA 1 (4) 1 (7) NS
PCA 2 (7) 1 (7) NS
VB 0 1 (7) NS
Microbleeds, n (%) (n = 25) (n = 24)
1 – 5 6 (24) 6 (25) NS
>5 1 (4) 0 NS
Post-stroke complications, n
(%)
Delirium 11 (30) 3 (7) 0.01
Mood disorder 3 (8) 2 (5) NS
Swallowing disorder 14 (38) 4 (10) 0.003
Seizure 0 1 (2) NS
Ischemic heart attack 1 (3) 3 (7) NS
Pulmonary infection 12 (32) 6 (15) NS
Urinary infection 3 (8) 1 (2) NS
Hemorrhagic transformation,
n (%)
20 (54) 5 (12) 0.002
HI 1 and 2 8 (40) 4 (80) NS
PH 1 and 2 12 (60) 1 (20) 0.003
Symptomatic intracranial
hemorrhage, n (%)
8 (22) 0 0.08
Duration of hospitalization,
mean (SD)
10 days (12) 7 days (9) 0.046
Table 2 Acute clinical and radiological status, post-stroke
outcome and stroke mechanisms (Continued)
mRS 0–2 at 3 months, n (%) 2 (5) 3 (7) NS
Post-stroke outcome, n (%)
Death≤ 7 days 8 (22) 4 (10) NS
Death > 7 days 6 (16) 6 (15) NS
Return to home 5 (14) 7 (17) NS
Rehabilitation center 10 (39) 7 (17) NS
Other medical
department
8 (22) 15 (37) NS
Nursing home 3 (8) 10 (24) NS




3 (8) 10 (24) NS
Cardioembolic (AF) 27 (73) 24 (59) NS
Small vessel disease 0 0 -
Other 0 1 (2) NS
Undetermined 7 (19) 6 (15) NS
NIHSS National Institute of Health Stroke Scale, ASPECTS Alberta Stroke Program
Early CT score, M1 - M2 - M3 segments of middle cerebral artery, ACA anterior
cerebral artery, PCA posterior cerebral artery, VB vertebral-basilar arteries, HI
hemorrhagic infarction, PH, parenchymal hemorrhage, AF atrial fibrillation,
NS non-significant
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Swallowing disorders and delirium were significantly
more frequent in the thrombolysed group. Swallowing
disorders appeared to be related to stroke severity, and
delirium to a side-effect of IV-tPA combined with the
effect of age. Delirium could also have been favored by
the cognitive frailty of these very elderly patients. In
addition, the decubitus often imposed in the acute phase
given the presence of a proximal intracranial occlusion
probably increased these disorders. The trend to more
frequent pulmonary infections in the thrombolysed
group might have been the consequence of swallowing
disorders in addition of agitation and altered awareness,
with the risk of getting in a vicious circle. These factors
might have contributed to impair the functional progno-
sis, increase mortality and interfere with the potential
benefit of thrombolysis.
The high rate of hemorrhagic transformation observed
in our population receiving IV-tPA (53 %) is in accord-
ance with the rate predicted by the SPAN-100 [27].
Hemorrhagic transformation and symptomatic intracra-
nial hemorrhage might also partly explain the absence of
IV-tPA benefit in the present study as we showed that
symptomatic intracranial hemorrhage tended to be
associated with the mRS at three months and death in
the first 7 days. However, in IST-3, symptomatic intra-
cranial hemorrhage did not affect clearly the outcome at
six months [23], and while thrombolysis was found to be
associated with hemorrhagic transformation in bivariate
analysis, it did not remain significant in multivariate
analysis. Conversely, intracranial occlusion and stroke
severity at 24 h were independent predictors of
hemorrhagic transformation. The association between
intracranial occlusion and hemorrhagic transformation
has already been described [28] and might be related to
the larger infarct size observed in this condition.
The results of this study should be interpreted cau-
tiously due to several limitations. First, the retrospective
design and the small sample size limits the power of
statistical analysis. But the characteristics of our popula-
tion are in line with previous studies and support the
validity of our sample. Second, IV-tPA was administered
until 4.5 h while some recommendations limit the use of
this treatment to 3 h post-stroke onset in patients older
than 80 y.o. [21]. However, treatment was initiated early
in our sample (mean 168 ± SD 48 min) which might
have limited the influence of the delay. Third, CTP im-
aging was not performed in non-thrombolysed patients,
which did not allow direct comparisons between groups.
Finally, the absence of evaluation of recanalization and/
or reperfusion and final infarct size also limits the inter-
pretation of results.
Conclusion
IV-tPA administered early after IS onset in our sample
of patients aged over 90 y.o. did not influence the func-
tional prognosis whereas most of them had a favorable
Table 3 Bivariate analyses of associations between pre-stroke and stroke characteristics and outcomes (linear regressions)
mRS at three months Hemorrhagic transformation Duration of hospitalization Death≤ 7 days
Estimate β (SE) p Estimate β (SE) p Estimate β (SE) p Estimate β (SE) p
Age −0.01 (0.1) 0.9 0.02 (0.04) 0.6 0.9 (0.7) 0.2 −0.03 (0.02) 0.3
Male −0.05 (0.05) 0.9 0.03 (0.1) 0.8 3.4 (2.5) 0.2 −0.1 (0.09) 0.1
Hypercholesterolemia −1.1 (0.4) 0.009 0.003 (0.1) 0.9 −1.9 (2.6) 0.5 −0.2 (0.09) 0.02
Statins −1 (0.5) 0.06 −0.06 (0.1) 0.7 −0.1 (3) 0.9 −0.1 (0.1) 0.3
Systolic blood pressure at baseline −0.0004 (0.008) 0.9 −0.003 (0.002) 0.2 −0.0003 (0.05) 0.9 −0.003 (0.002) 0.07
NIHSS at baseline 0.08 (0.03) 0.008 0.02 (0.009) 0.01 0.2 (0.2) 0.4 0.02 (0.006) 0.002
NIHSS at 24 h 0.09 (0.02) <.001 0.03 (0.008) 0.003 0.07 (0.2) 0.7 0.03 (0.005) <.001
Intracranial occlusion 1.04 (0.4) 0.01 0.4 (0.1) 0.002 2.9 (2.5) 0.2 0.03 (0.08) 0.7
Thrombolysis 0.2 (0.4) 0.6 0.4 (0.1) 0.002 2.7 (2.4) 0.3 0.1 (0.08) 0.2
Hemorrhagic transformation 0.8 (0.4) 0.04 - - 2.3 (2.8) 0.4 0.1 (0.09) 0.1
Symptomatic intracranial hemorrhage 1 (0.4) 0.03 - - −5.2 (6.4) 0.4 0.6 (0.2) <.001
Cardioembolic stroke subtype (AF) 0.9 (0.4) 0.053 −0.03 (0.1) 0.8 4.6 (2.5) 0.07 0.07 (0.09) 0.4
Large artery atherosclerosis stroke subtype −0.09 (0.6) 0.9 −0.05 (0.2) 0.8 −4.8 (3.2) 0.1 −0.09 (0.1) 0.4
SE standard error, AF atrial fibrillation
Table 4 Predictors of hemorrhagic transformation in
multivariate analysis (multiple linear regressions)
Hemorrhagic transformation
Estimate β (SE) p
NIHSS at baseline −0.002 (0.01) 0.8
NIHSS at 24 h 0.03 (0.01) 0.006
Intracranial occlusion 0.3 (0.1) 0.02
Thrombolysis 0.03 (0.1) 0.8
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neuroimaging pattern. Moreover, hemorrhagic trans-
formation and post-stroke complications were more
frequent in thrombolysed patients, and symptomatic
intracranial hemorrhage tended to worsen the functional
outcome at three months and increase the rate of death
in the first 7 days.
While the identification of additional predictors could
be useful to improve the selection of patients suitable
for IV-tPA, other revascularization techniques such as
mechanical thrombectomy might be considered in this
frail population in order to reduce hemorrhagic trans-
formation, early clinical worsening, the vicious circle of
post-stroke complications and extended duration of
hospitalization. Further studies are needed to confirm
those results.
Additional file
Additional file 1: Table S1. Multivariate analysis of associations
between pre-stroke and stroke characteristics, mRS at three months and
death in the first 7 days (multiple linear regressions). (DOCX 22 kb)
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